These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12211096)

  • 1. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
    Yamada Y; Ohno Y; Nakashima Y; Fukuda M; Takayanagi R; Sato H; Tsuchiya F; Sawada Y; Iga T
    Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
    Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
    Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable.
    Medori R; Mannaert E; Gründer G
    Eur Neuropsychopharmacol; 2006 May; 16(4):233-40. PubMed ID: 16326078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of D(2) and D(3) receptor activity in vivo: PET scan and prolactin.
    Thomasson-Perret N; Pénélaud PF; Théron D; Gouttefangeas S; Mocaër E
    Therapie; 2008; 63(3):237-42. PubMed ID: 18718212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
    Matsui-Sakata A; Ohtani H; Sawada Y
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
    Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
    Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK; Brennum LT; Kreilgaard M
    Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic malignant syndrome with risperidone.
    Gleason PP; Conigliaro RL
    Pharmacotherapy; 1997; 17(3):617-21. PubMed ID: 9165568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
    Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
    Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
    Knable MB; Heinz A; Raedler T; Weinberger DR
    Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
    Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
    Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
    Kapur S; Remington G; Zipursky RB; Wilson AA; Houle S
    Life Sci; 1995; 57(10):PL103-7. PubMed ID: 7543969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
    Uchida H; Mamo DC; Pollock BG; Suzuki T; Tsunoda K; Watanabe K; Mimura M; Bies RR
    Ther Drug Monit; 2012 Apr; 34(2):182-7. PubMed ID: 22377743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.